Butantan Institute files for CoronaVac emergency approval

emergency use coronavac
São Paulo officials present CoronaVac efficacy rates. Photo: GOVESP

The Brazilian National Health Surveillance Agency (Anvisa) received a request for the emergency approval of Chinese-made coronavirus vaccine CoronaVac on Friday. The petition was filed by São Paulo’s Butantan Institute — which carried out CoronaVac clinical trials in Brazil — following a deal with the federal government for 100 million doses.

Anvisa officials say clearance could come within ten days — but the agency may extend the deadline if further information is necessary.

On January 7, Butantan announced that CoronaVac has a 78-percent efficacy rate against mild Covid-19 infections — and 100 percent for severe cases. However, the institute offered no further details on the clinical trial results.

Support this coverage →Support this coverage →